ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

ALXO Interest Expense

Cost of servicing the company's debt during the period.

ALX Oncology Holdings Inc.NASDAQ: ALXO

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $331K fell 18.5% year over year, behind the -10.6% change in trailing-twelve-month interest expense. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at +88.8% a year.

Context

  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -18.5% toward the trailing-twelve-month pace of -10.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$331K-13.6% QoQ
Last fiscal yearDec 2025
$1.6M-7.3% YoY
LTMMar 2026
$1.53M-10.6% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.5%——
1 year-7.3%——
3-year CAGR+88.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
1.6M USD
Year-over-year change
-7.3%
4-year CAGR
+233.2%

Interest Expense vs competitors

How ALXO compares with its peers on the latest reported figures

  • ALXO's LTM Mar 2026 interest expense of $1.53M is the 2nd highest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -10.6% is the 2nd highest of 4, against a peer median of -29.4%.
  • Over three fiscal years its annual growth of +88.8% compares with a peer median of -24.1%.
ALXO Competitors Peer median
Interest Expense for ALXO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STOKStoke Therapeutics, Inc.LTM Mar 2026$3.41M +340500.0%—10.6%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$1.53M -10.6%+88.8%—
KYMRKymera Therapeutics, Inc.LTM Jun 2026$211K -29.4%+12.3%0.2%
BCYCBicycle Therapeutics plcLTM Mar 2026$203K -78.9%-60.5%0.3%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
ANNXAnnexon, Inc.LTM Mar 2026$0 ———
NKTXNkarta, Inc.LTM Mar 2026$0 ———
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ALXO) $0-29.4%-24.1%0.2%

Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development60.17M98.4M141.8M116.37M77M
Selling, General & Admin23.39M29.04M28.48M26.09M23.85M
Operating Expenses83.56M127.44M170.28M142.47M104.02M
Depreciation & Amortization51K342K836K872K706K
EBITDA(83.42M)(122.84M)(158.4M)(132.25M)(99.39M)
EBITDA Margin—————
Operating Income(83.56M)(127.44M)(170.28M)(142.47M)(104.02M)
Operating Margin—————
Interest Income914.28M10.65M9.37M3.96M
Interest Expense13K238K1.57M1.73M1.6M
Other Income / Expenses71K4.02M9.47M7.62M2.33M
Income Before Tax(83.48M)(123.42M)(160.81M)(134.85M)(101.7M)
Pre-Tax Margin—————
Income Tax Expense(21K)64K000
Net Income(83.46M)(123.48M)(160.81M)(134.85M)(101.7M)
Net Margin—————
EPS (Basic)(2.07)(3.03)(3.74)(2.58)(1.90)
EPS (Diluted)(2.07)(3.03)(3.74)(2.58)(1.90)
Weighted Avg Shares40.31M40.7M42.99M52.17M53.66M
Weighted Avg Shares (Diluted)40.31M40.7M42.99M52.17M53.66M

ALX Oncology Holdings Inc.

NASDAQ:ALXO

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.